Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy
出版年份 2015 全文链接
标题
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume 15, Issue 12, Pages 1389-1403
出版商
Informa UK Limited
发表日期
2015-11-12
DOI
10.1586/14737140.2015.1115725
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Metastatic Melanoma – A Review of Current and Future Treatment Options
- (2015) E Maverakis et al. ACTA DERMATO-VENEREOLOGICA
- The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date
- (2015) Katy K. Tsai et al. DRUGS
- Gauging the Long-Term Benefits of Ipilimumab in Melanoma
- (2015) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune checkpoint modulation: Rational design of combination strategies
- (2015) Dmitriy Zamarin et al. PHARMACOLOGY & THERAPEUTICS
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
- (2015) L. G. Ahronian et al. Cancer Discovery
- Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
- (2014) John F. Thompson et al. ANNALS OF SURGICAL ONCOLOGY
- Biosafety of Gene Therapy Vectors Derived From Herpes Simplex Virus Type 1
- (2014) Filip Lim et al. CURRENT GENE THERAPY
- Intralesional therapy for metastatic melanoma
- (2014) Sarah Sloot et al. EXPERT OPINION ON PHARMACOTHERAPY
- Combinatorial Approach to Treatment of Melanoma
- (2014) Michelle T. Ashworth et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Combinations of Radiation Therapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes
- (2014) Christopher A. Barker et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses
- (2014) B. Weide et al. Cancer Immunology Research
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression
- (2014) Damya Laoui et al. Frontiers in Immunology
- Treating advanced melanoma: current insights and opportunities
- (2014) Michael Tronnier et al. Cancer Management and Research
- Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
- (2014) Robert HI Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma
- (2014) Howard L Kaufman et al. Journal for ImmunoTherapy of Cancer
- Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
- (2014) Mizuki Nishino et al. Journal for ImmunoTherapy of Cancer
- Pharmacological Modulation of Anti-Tumor Immunity Induced by Oncolytic Viruses
- (2014) Nicole E. Forbes et al. Frontiers in Oncology
- Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
- (2013) Howard L. Kaufman et al. Nature Reviews Clinical Oncology
- Challenge of Primary Tumor Management in Patients With Stage IV Colorectal Cancer
- (2012) George J. Chang JOURNAL OF CLINICAL ONCOLOGY
- Oncolytic virotherapy
- (2012) Stephen J Russell et al. NATURE BIOTECHNOLOGY
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
- (2011) Alan Melcher et al. MOLECULAR THERAPY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck
- (2010) K. J. Harrington et al. CLINICAL CANCER RESEARCH
- OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma
- (2010) Howard L Kaufman et al. Future Oncology
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
- (2009) Howard L. Kaufman et al. ANNALS OF SURGICAL ONCOLOGY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
- (2009) Neil N. Senzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy
- (2009) Marianna Sabatino et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started